These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

968 related articles for article (PubMed ID: 22158541)

  • 21. Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors.
    Scott LM; Rebel VI
    J Natl Cancer Inst; 2013 Oct; 105(20):1540-9. PubMed ID: 24052622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recurrent gene mutations in CLL.
    Martínez-Trillos A; Quesada V; Villamor N; Puente XS; López-Otín C; Campo E
    Adv Exp Med Biol; 2013; 792():87-107. PubMed ID: 24014293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia.
    Wang L; Brooks AN; Fan J; Wan Y; Gambe R; Li S; Hergert S; Yin S; Freeman SS; Levin JZ; Fan L; Seiler M; Buonamici S; Smith PG; Chau KF; Cibulskis CL; Zhang W; Rassenti LZ; Ghia EM; Kipps TJ; Fernandes S; Bloch DB; Kotliar D; Landau DA; Shukla SA; Aster JC; Reed R; DeLuca DS; Brown JR; Neuberg D; Getz G; Livak KJ; Meyerson MM; Kharchenko PV; Wu CJ
    Cancer Cell; 2016 Nov; 30(5):750-763. PubMed ID: 27818134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease.
    Rodríguez-Vicente AE; Díaz MG; Hernández-Rivas JM
    Cancer Genet; 2013 Mar; 206(3):49-62. PubMed ID: 23531595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.
    Guièze R; Robbe P; Clifford R; de Guibert S; Pereira B; Timbs A; Dilhuydy MS; Cabes M; Ysebaert L; Burns A; Nguyen-Khac F; Davi F; Véronèse L; Combes P; Le Garff-Tavernier M; Leblond V; Merle-Béral H; Alsolami R; Hamblin A; Mason J; Pettitt A; Hillmen P; Taylor J; Knight SJ; Tournilhac O; Schuh A
    Blood; 2015 Oct; 126(18):2110-7. PubMed ID: 26316624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spliceosome mutations in hematopoietic malignancies.
    Hahn CN; Scott HS
    Nat Genet; 2011 Dec; 44(1):9-10. PubMed ID: 22200771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.
    Stilgenbauer S; Schnaiter A; Paschka P; Zenz T; Rossi M; Döhner K; Bühler A; Böttcher S; Ritgen M; Kneba M; Winkler D; Tausch E; Hoth P; Edelmann J; Mertens D; Bullinger L; Bergmann M; Kless S; Mack S; Jäger U; Patten N; Wu L; Wenger MK; Fingerle-Rowson G; Lichter P; Cazzola M; Wendtner CM; Fink AM; Fischer K; Busch R; Hallek M; Döhner H
    Blood; 2014 May; 123(21):3247-54. PubMed ID: 24652989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages.
    Gentien D; Kosmider O; Nguyen-Khac F; Albaud B; Rapinat A; Dumont AG; Damm F; Popova T; Marais R; Fontenay M; Roman-Roman S; Bernard OA; Stern MH
    Leukemia; 2014 Jun; 28(6):1355-7. PubMed ID: 24434863
    [No Abstract]   [Full Text] [Related]  

  • 29. SF3B1 mutations constitute a novel therapeutic target in breast cancer.
    Maguire SL; Leonidou A; Wai P; Marchiò C; Ng CK; Sapino A; Salomon AV; Reis-Filho JS; Weigelt B; Natrajan RC
    J Pathol; 2015 Mar; 235(4):571-80. PubMed ID: 25424858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia.
    Rossi D; Spina V; Bomben R; Rasi S; Dal-Bo M; Bruscaggin A; Rossi FM; Monti S; Degan M; Ciardullo C; Serra R; Zucchetto A; Nomdedeu J; Bulian P; Grossi A; Zaja F; Pozzato G; Laurenti L; Efremov DG; Di-Raimondo F; Marasca R; Forconi F; Del Poeta G; Gaidano G; Gattei V
    Blood; 2013 Jun; 121(24):4902-5. PubMed ID: 23637131
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    López-Oreja I; Gohr A; Playa-Albinyana H; Giró A; Arenas F; Higashi M; Tripathi R; López-Guerra M; Irimia M; Aymerich M; Valcárcel J; Bonnal S; Colomer D
    Life Sci Alliance; 2023 Nov; 6(11):. PubMed ID: 37562845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alteration of the SETBP1 gene and splicing pathway genes SF3B1, U2AF1, and SRSF2 in childhood acute myeloid leukemia.
    Choi HW; Kim HR; Baek HJ; Kook H; Cho D; Shin JH; Suh SP; Ryang DW; Shin MG
    Ann Lab Med; 2015 Jan; 35(1):118-22. PubMed ID: 25553291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Altered DNA Methylation Profiles in
    Pacholewska A; Grimm C; Herling CD; Lienhard M; Königs A; Timmermann B; Altmüller J; Mücke O; Reinhardt HC; Plass C; Herwig R; Hallek M; Schweiger MR
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients.
    Mansouri L; Grabowski P; Degerman S; Svenson U; Gunnarsson R; Cahill N; Smedby KE; Geisler C; Juliusson G; Roos G; Rosenquist R
    Am J Hematol; 2013 Aug; 88(8):647-51. PubMed ID: 23620080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features.
    Morabito F; Mosca L; Cutrona G; Agnelli L; Tuana G; Ferracin M; Zagatti B; Lionetti M; Fabris S; Maura F; Matis S; Gentile M; Vigna E; Colombo M; Massucco C; Recchia AG; Bossio S; De Stefano L; Ilariucci F; Musolino C; Molica S; Di Raimondo F; Cortelezzi A; Tassone P; Negrini M; Monti S; Rossi D; Gaidano G; Ferrarini M; Neri A
    Clin Cancer Res; 2013 Nov; 19(21):5890-900. PubMed ID: 24036852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia.
    Ouillette P; Saiya-Cork K; Seymour E; Li C; Shedden K; Malek SN
    Clin Cancer Res; 2013 Jun; 19(11):2893-904. PubMed ID: 23620403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.
    Oscier DG; Rose-Zerilli MJ; Winkelmann N; Gonzalez de Castro D; Gomez B; Forster J; Parker H; Parker A; Gardiner A; Collins A; Else M; Cross NC; Catovsky D; Strefford JC
    Blood; 2013 Jan; 121(3):468-75. PubMed ID: 23086750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG.
    Schnaiter A; Paschka P; Rossi M; Zenz T; Bühler A; Winkler D; Cazzola M; Döhner K; Edelmann J; Mertens D; Kless S; Mack S; Busch R; Hallek M; Döhner H; Stilgenbauer S
    Blood; 2013 Aug; 122(7):1266-70. PubMed ID: 23821658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rare SF3B1 R625 mutations in cutaneous melanoma.
    Kong Y; Krauthammer M; Halaban R
    Melanoma Res; 2014 Aug; 24(4):332-4. PubMed ID: 24709888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of SF3B1 mutations in monoclonal B-cell lymphocytosis.
    Greco M; Capello D; Bruscaggin A; Spina V; Rasi S; Monti S; Ciardullo C; Cresta S; Fangazio M; Gaidano G; Foà R; Rossi D
    Hematol Oncol; 2013 Mar; 31(1):54-5. PubMed ID: 22461140
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.